Summary This Policy Review presents the International Myeloma Working Group's clinical
practice recommendations for the treatment of relapsed and refractory multiple myeloma …

The signaling lymphocytic activation molecule (SLAM) family receptors were discovered in
immune cells for the first time. The SLAM-family receptors are a significant player in …

PURPOSE At the primary analysis of CASTOR (median follow-up, 7.4 months),
daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged …

The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several
new options. These include new combinations with second generation proteasome …

PURPOSE In the phase II ELOQUENT-3 trial (ClinicalTrials. gov identifier: NCT02654132),
elotuzumab combined with pomalidomide/dexamethasone (EPd) significantly improved …

Background Elotuzumab plus lenalidomide and dexamethasone has shown improved
progression-free and overall survival versus lenalidomide and dexamethasone in patients …

From a historic lens, treatment for patients with relapsed/refractory multiple myeloma (R/R
MM) has advanced significantly since the advent of immunomodulatory agents (IMiDs) in the …

Despite recent advances, multiple myeloma remains an incurable disease for most patients,
and initial remission will be followed by relapses requiring therapy. For many, there will be …

Multiple myeloma (MM) remains an incurable hematological malignancy disease
characterized by the progressive dysfunction of the patient's immune system. In this context …

The landscape of therapeutic measures to treat multiple myeloma has undergone a seismic
shift since the dawn of the current century. This has been driven largely by the introduction of …